Research article · 24 May 2024
Research articlePublished 2015
Phase 1 Dose-Escalation Study with LEC/Chtnt-3 and Toceranib Phosphate (Palladia) in Dogs with Spontaneous Malignancies
Abstract
Select any words in the title or abstract, or press this and choose a sentence.
Objectives: LEC chemokine promotes TH1 responses and recruits immune cells to inflammatory sites. By linking LEC to an antibody targeting tumor necrosis, LEC/chTNT-3 can be used for the immunotherapeutic treatment of tumors. The primary objective of this study was to determine the safety profile of LEC/chTNT-3 and toceranib phosphate (Palladia®) combination therapy in dogs with spontaneous malignancies. Secondary purpose was to determine objective responses to treatment. Methods: Twenty-three dogs with cancer were enrolled, covering nine different malignancies. In this dose escalation study, dogs received LEC/chTNT-3 for five days, and toceranib every 48 hours for the remainder of the study. Dogs received physical exams, chemistry panel, urinalysis, and complete blood counts on days 0, 10, 28 of the study, and every 6-8 weeks thereafter. Results: Lethargy was noted in 13% dogs. There were no statistical differences in the prevalence of anorexia, diarrhea, thrombocytopenia, renal toxicity, or hepatic toxicity before or during the study. There were trends in increases in the prevalence of vomiting, lymphopenia, and neutropenia (all grade 2 or lower, p=0.07) over the initial 28 days of the study. By day 28, 10% of dogs had partial responses, 58% had stable disease, and 32% had progressive disease. Conclusions: LEC/chTNT-3 and toceranib were well tolerated. This combination therapy showed some biological activity against a variety of cancers at a low dose and short duration of LEC/chTNT-3 administration.
Subjects
Oncology & CancerAsk about this article
Answers come only from this article's title, abstract and keywords, each sentence pointing to where it comes from. Your question is sent to OpenAI to write the answer. Scholars Central does not store it.
Similar by topic
Research article · 26 Aug 2021
Designing a Pragmatic Dose-Escalation for Vitamin-D to Reduce Endometriosis Related Pain after Laparoscopy in Vitamin- D Deficient Women
Conference abstract · 2013
A randomized, placebo-controlled, single-blind, dose-escalation, first-time-in-human study to assess the safety and pharmacokinetics of single and repeat doses of srt3025 in normal healthy volunteers
Conference abstract
A first-in-man phase I study of Photochemical Internalisation (PCI) of bleomycin with TPCS2a in patients with solid malignancies – a dose escalation study showing promising signs of efficacy
Conference abstract · 1 Sep 2015
Sensibility cell block (FNA) for detection of CK5, ER and PR in spontaneous mammary carcinoma in female dogs
More from this journal
The newest in Cancer Science & Therapy.
Commentary · 21 Feb 2026
Functional Immune Biomarker Identification in Patients with Breast Cancer
Perspective · 21 Feb 2026
Finding Potential Passerini Adducts for Anticancer Drug Development
Perspective · 21 Feb 2026
Head and Neck Cutaneous Squamous Cell Carcinoma with Perineural Invasion
Conferences in this field
Upcoming conferences in this field.
Follow
New articles from what you follow go into your email digest, once you agree to alert emails.
- JournalCancer Science & Therapy
- SubjectOncology & Cancer
- BylineArticles whose byline prints “Julie K. Jang”
- BylineArticles whose byline prints “John Chretin”
- BylineArticles whose byline prints “David Bruyette”
- BylineArticles whose byline prints “Peisheng Hu”
- BylineArticles whose byline prints “Alan L. Epstein”

